172 countries and multiple candidate vaccines engaged in COVID-19 vaccine Global Access Facility
On Aug. 23, 2020, the World Heath Organization (WHO) reported that 172 economies were engaged in discussions to…
Novavax initiated efficacy trial of COVID-19 vaccine in South Africa
On Aug. 17, 2020, Novavax announced the beginning of a Phase 2b clinical trial in South Africa to…
Vaccine refusal and measles outbreaks increased in the U.S.
On Aug. 14, 2020, in the U.S., despite high rates of coverage (>90%) at the national level for…
Novavax and UK Government announced collaboration and purchase agreement for Novavax’ COVID-19 vaccine candidate
On Aug. 14, 2020, Novavax announced it had signed a Heads of Terms (Term Sheet) with the Government…
Novavax and SK bioscience announced collaboration for Novavax COVID-19 vaccine candidate
On Aug. 13, 2020, Novavax and SK bioscience announced a development and supply agreement for the antigen component…
Moderna announced supply agreement with U.S. Government for initial 100 million doses of mRNA vaccine against COVID-19
On Aug. 11, 2020, Moderna announced that the U.S. government had secured 100 million doses of mRNA-1273. The…
Scientists revealed structural details of spike protein used in leading COVID-19 vaccine
On Aug. 7, 2020, scientists at Scripps Research announced they had obtained high-resolution, atomic-scale details of the structure…
Biotechnology | COVID-19 | Infectious Disease | Life Science News | Nanotechnology | Pharmaceutical | Vaccine
Novavax and Takeda announced collaboration for Novavax COVID-19 vaccine candidate in Japan
On Aug. 7, 2020, Novavax and Takeda Pharmaceutical announced a partnership for the development, manufacturing and commercialization of…
Biotechnology | COVID-19 | Infectious Disease | Life Science News | Nanotechnology | Therapeutics | Vaccine
Novavax signed COVID-19 vaccine supply deal with India’s Serum Institute
On Aug. 6, 2020, Novavax announced it had entered a supply and license agreement with the Serum Institute…
NIH-Moderna investigational COVID-19 vaccine showed promise in mouse studies
On Aug. 5, 2020, the National Institute of Allergy and Infectious Diseases (NIAID) announced that the investigational vaccine…
Novavax announced positive phase 1 data for its COVID-19 vaccine candidate
On Aug. 4, 2020, Novavax announced Phase 1 data from its Phase 1/2 randomized, observer-blinded, placebo-controlled trial of…
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Life Science News | Non-Profit Research | Oncology
Pathnova Laboratories announced partnership to commercialize Todos Medicals COVID-19 and breast cancer tests in Singapore
On Aug. 3, 2020, Todos Medical announced a partnership with PATHNOVA, a Singapore-based clinical laboratory, for the Company’s…
Serum Institute of India received approval to start human trials for Oxford vaccine
On Aug. 1, 2020, Novavax announced it had received approval to start human trials in India for the…
Researchers reported fat-based molecules key to Zika virus infection
On Jul. 31, 2020, researchers from the Pacific Northwest National Laboratory (PNNL) and Oregon Health & Science University…
Seqirus began shipping 2020/21 influenza vaccines to U.S. market
On Jul. 30, 2020, Seqirus announced it had begun shipping its portfolio of seasonal influenza vaccines to customers…
INOVIO’s COVID-19 DNA vaccine INO-4800 provided protection with memory immune responses In non-human primates challenged with SARS-CoV-2 virus
On Jul. 30, 2020, INOVIO announced that its COVID-19 DNA vaccine INO-4800 targeting SARS-CoV-2 was effective in protecting…
BARDA procured Regeneron’s REGN-EB3 investigational Ebola treatment for national preparedness
On Jul. 29, 2020, Regeneron announced that the Biomedical Advanced Research and Development Authority (BARDA) had entered into…
Sanofi and GSK agreed with the UK government to supply up to 60 million doses of COVID-19 vaccine
On Jul. 29, 2020, Sanofi and GSK announced an agreement with the UK government for the supply of…
Moderna announced publication in the NEJM of non-human primate preclinical viral challenge study of its mRNA vaccine against COVID-19
On Jul. 28, 2020, Moderna announced a preclinical study evaluating mRNA-1273, its vaccine candidate against COVID-19, was published…
Phase 3 clinical trial of investigational vaccine for COVID-19 began
On Jul. 27, 2020, the National Institutes of Health (NIH) announced that a phase 3 clinical trial designed…
MediciNova announced SARS-CoV-2 vaccine joint development with BioComo and Mie University Japan
On Jul. 27, 2020, MediciNova announced an agreement with BioComo and Mie University (Mie prefecture, Japan) for joint…
Moderna announced phase 3 COVE study of mRNA vaccine against COVID-19 (mRNA-1273) began
On Jul. 27, 2020, Moderna announced that the Phase 3 study of its mRNA vaccine candidate (mRNA-1273) against…
Texas A&M College Station Bio-Manufacturing Center to produce COVID-19 vaccines
On Jul. 27, 2020, FUJIFILM Diosynth Biotechnologies (FDB) and Texas A&M announced they mass will produce vaccines as…
Moderna announced expansion of BARDA agreement to support larger phase 3 program for vaccine (mRNA-1273) against COVID-19
On Jul. 26, 2020, Moderna announced a modification to its contract with the Biomedical Advanced Research and Development…
Novavax and FUJIFILM Diosynth Biotechnologies initiated large scale manufacturing of COVID-19 vaccine candidate
On Jul. 23, 2020, Novavax and FUJIFILM Diosynth Biotechnologies announced an agreement to manufacture bulk drug substance for…
Experimental Coronavirus vaccine is safe and produced immune response
On Jul. 21, 2020, National Institutes of Health (NIH) researchers reported early results from the first COVID-19 vaccine…
Experimental coronavirus vaccine reported safe and produces immune response
On Jul. 21, 2020, researchers from the National Institutes of Health (NIH) announced that early results from the…
Dynavax and Mount Sinai announced collaboration to develop a universal influenza vaccine candidate with CpG 1018 adjuvant
On Jul. 16, 2020, Dynavax Technologies and the Icahn School of Medicine at Mount Sinai announced they had…
Tevogen Bio announced steps toward proprietary T Cell therapy for development of bivalent vaccine for COVID-19 and influenza
On Jul. 15, 2020, Tevogen Bio announced its intention to evaluate its proprietary antigen-specific T cell technology as…
Moderna announced publication in The New England Journal of Medicine of interim results from phase 1 study of its mRNA vaccine against COVID-19
On Jul. 14, 2020, Moderna announced the publication of an interim analysis of the open-label Phase 1 study…